Evaluate Releases Updated Pharmaceutical Market Forecasts in Annual World Preview Report

The 2025 report highlights China’s rapid biopharma rise, along with steady global growth and booming biologics  

LONDON – 24 June 2025 – Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 World Preview Report, offering updated insights for the global pharmaceutical market through 2030. The report projects worldwide prescription pharmaceutical sales to grow at a CAGR of over 7% into 2030, with the fastest five growing therapeutic areas being: GLP-1s (metabolic disease), oncology, immunology, central nervous system and cardiovascular diseases.

China dominates biopharma signaling fundamental industry change

Amid unpredictable US pricing shifts, tariffs, FDA changes, and global economic uncertainty, China emerged as a major force in the market that will undeniably upend the biopharma world order. China’s burgeoning biopharma sector is churning out me-better and even first-in-class molecules in high volumes, with high efficiency. China-sourced assets accounted for just 3% of all licensing deals in 2020, yet in 2025 will make up almost 40%.

“There is a reassuring continuity to the 2025 World Preview Report’s data compared to last year, with familiar drivers like GLP-1s, biologics, and immunology remaining resilient within the market. However, there are certainly signs of fundamental change brewing, particularly when looking at China. Global competition, evolving regulatory dynamics, and new sources of innovation will inevitably reshape the industry, and time will tell which factors hold the most weight,” said Daniel Chancellor, Vice President of Thought Leadership at Norstella, Evaluate’s parent company.

While China’s potential to upend the market grows, the World Preview Report outlines other significant movement to look out for in the sector, including:

• GLP-1 agonists and related combinations are now in a class of their own. They are expected to grow at a turbo-charged 20% per annum (compounded) between 2024 and 2030, and to comprise close to 9% of all prescription drug sales by the end of the decade.
• Immuno-inflammatory disease drugs: AbbVie’s Skyrizi and Sanofi’s Dupixent feature among 2030’s top ten best-sellers.
• Biologics’ relentless march: By 2030, biologics will account for 57% of the global pharma value pie, and over 70% of the top 100 products.

Additional analysis is included in the full report, which is available here, and a webinar featuring discussion and insight from the report will take place on 1^st July. Registration is available here.